Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Descrizione del progetto

Nuovi farmaci che superano la resistenza agli antibiotici potrebbero essere destinati alle sperimentazioni cliniche

I batteri Gram-negativi hanno una membrana esterna che impedisce agli antibiotici di penetrare. L’aumento della multifarmacoresistenza nei batteri Gram-negativi sta diventando una grande sfida per la salute pubblica e il progetto GNA NOW, finanziato dall’UE, sta crescendo per affrontarlo. Nell’ambito del nuovo programma Antimicrobial Resistance Accelerator (AMR) dell’UE, gli esperti accademici e del settore intendono scoprire e testare i composti antibiotici più promettenti per i prossimi sei anni e portare parte di essi alle sperimentazioni cliniche.

Obiettivo

AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.

Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

STICHTING LYGATURE
Contribution nette de l'UE
€ 757 556,25
Indirizzo
JAARBEURSPLEIN 6
3521 AL Utrecht
Paesi Bassi

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage
Tipo di attività
Other
Collegamenti
Costo totale
€ 757 556,25

Partecipanti (12)